BRCA2 and ovarian serous adenocarcinoma: The finding in our manuscript that 21.3% of serous ovarian cancer patients were germline BRCA1 or BRCA2 mutation carriers is consistent with previous research reporting a 20% and 23% germline mutation rate in HGSC patients [9, 10, 25].